|A unique collection of 60 Toxicity natural compounds for screening|
|Catalog No:||Bb201|| Toxicity Compound Library
|Size:||1mg/well * 60 Compounds|
2mg/well * 60 Compounds
1. Alpha-Solanine alters antioxidative enzyme activities and MDA and PCO concentrations and GST activity in fat body and midgut.
2. Alpha-Solanine has proliferation-inhibiting and apoptosis-promoting effect on multiple cancer cells, such as clone, liver, melanoma cancer cells.
1. 3-O-(2'E ,4'Z-decadienoyl)-20-deoxyingenol, one toxic terpenoid from raw Gansui.
2. 3-O-(2′E,4′Z-decadienoyl)-20-O-acetylingenol has strong cytotoxicity against human normal cell lines L-O2 and GES-1 with dose-dependent relationships.
3. 3-O-(2′E,4′Z-decadienoyl)-20-O-acetyl-ingenol and 3-O-(2′E,4′E-decadienoyl)-ingenol show cytotoxicity on Namalwa cells with IC 50 values of 7.6 and 5.2 umol·L-1, respectively.
1. Kansuinine A possesses analgesic props.
2. Kansuinine A shows NGF inducing activity.
1. 3-O-(2′E,4′Z-decadienoyl)-20-O-acetylingenol, one toxic terpenoid from raw Gansui.
2. 3-O-(2′E,4′Z-decadienoyl)-20-O-acetylingenol has strong cytotoxicity against human normal cell lines L-O2 and GES-1 with dose-dependent relationships .
3. 20-O-acetyl-[3-O-(2'E,4'Z)-decadienoyl]-ingenol and 3-O-(2'E,4'Z)-decadienoylingenol show the same antinematodal activity against the nematode, Bursaphelenchus xylophilus, at a minimum effective dose (MED) of 5 microg/cotton ball.
4. 3-O-(2'E,4'Z-decadienoyl)-20-O-acetylingenol induces the cytotoxicity of intestinal epithelial cells of rats (IEC-6 cells) depends on induction of cell apoptosis via mitochondrial pathway and cell cycle arrest.
5. 3-O-(2'E,4'Z-decadienoyl)-20-O-acetylingenol, kansuinine B and kansuinine A can markedly promote SPL proliferation and NO production by PMphi at concentrations from 0.78 to 12.50 microg/mL, hence the they are believed to be important proinflammatory components of the roots of E. kansui.
1. Kansuinine B shows cytotoxic activity.
2. Kansuinine B shows analgesic activity.
3. Treatment with kansuinine B and kansuinine A represents a novel method to block the IL-6-induced effects.